Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Mark Mallon was last confirmed as CEO and Board Member at Neogenomics Inc (NEO) in a filing dated April 7, 2023. Earlier roles on record: CEO at Ironwood Pharmaceuticals Inc (IRWD) until March 12, 2021. Mark Mallon has spoken on 7 earnings calls across 2 companies, most recently for Neogenomics Inc on February 23, 2022.
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
Start not stated–2023-04-07
Last confirmed by a filing; no departure on record
Start not stated–2023-04-07
Last confirmed by a filing; no departure on record
Start not stated–2021-03-12
Recorded roles and call appearances connecting this person to public companies.
NEO
CEO, Board Member
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
